You searched for "safety"

471 results found

Steroid safety in MG treatment

This study was conducted to evaluate the efficacy and safety of low to moderate dose oral steroids in patients diagnosed with ocular myasthenia gravis (MG). This was a retrospective case series. The study reviewed 23 patients; 15 males and eight...

Ranibizumab safety in pregnancy

Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

Patient safety – is this achieved in optometry with CET?

Collecting points and ticking boxes – as we come to the end of another three year cycle of continuing education and training (CET), the rush to ensure that everything has been completed on the myGOC (General Optical Council) dashboard feels...

Safety and outcome of microincision vitreous surgery in uveitis

This paper reports the outcomes of microincision vitreous surgery (MIVS) 23G/25G in uveitis of 103 patients (106 eyes) who underwent diagnostic MIVS over a period of four years at the Advanced Eye centre in Chandigarth India. The postoperative evaluation included...

Retrospective safety assessment of apraclonidine for diagnosis of Horner’s syndrome in children

Apraclonidine has been shown to reverse the anisocoria in Horner’s syndrome, with some reports of partial ptosis resolution. Side-effects of apraclonidine have been reported especially in children under six months old. The authors present a retrospective safety study of using...

One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management

The authors report a retrospective, non-randomised interventional case series of 39 patients who underwent a standalone XEN45 implantation. All 39 patients (female: male=1.2: 1) completed 12-month follow-up. Mean age was 70.1 years (range 32–92). Primary outcome measures were the intraocular...

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration

This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...

Changing the post cataract surgery review pathway – is patient safety compromised?

Cataract surgery continues to be the most commonly performed elective surgical procedure in the UK, with an annual rate of approximately 4150/100,000 people over the age of 65 accounting for a significant proportion of the surgical workload of most ophthalmologists...

Efficacy and safety of novel PF brimonidine / timolol fixed-combination ophthalmic solution for OAG

This study is a multicentre, randomised, open-label, parallel-group clinical trial to evaluate the efficacy and safety of a newly developed preservative-free (PF) brimonidine / timolol fixed-combination (BTFC) ophthalmic solutions as compared with preservative-containing (PC) BTFC ophthalmic solution in adult patients...

Effectiveness and Safety of Dexamethasone implants for post surgical macular oedema including Irvine-gass syndrome

This is a retrospective, multicentre, uncontrolled, consecutive case series from Lyon, France between April 20111 to June 2014, with minimum of one year follow-up. The clinical features including the best corrected acuity (BCVA), central subfield macular thickness (CSMT) and intraocular...

Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO

This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...